Fig. 4. BDNF inhibitor effectively reduced pain behavior and spinal astrocytic BDNF. (A) Experimental timeline for BDNF inhibitor injection during acute pain period, ANA12 was injected at 0.5 mg/kg on day 6 and day 7 post injury. (B) (Left) Percentage of withdrawal threshold within 7 days post injury with and without ANA12 injection, (Right) bar graphs represent significant differences in percentage of withdrawal threshold among three groups on day 0, day 6 and day 7 post injury. Ordinary one-way ANOVA with Tukey’s multiple comparison test (**p=0.009, ***p<0.001, ns: non-significant, p>0.05). (C) Experimental timeline for BDNF inhibitor injection during chronic pain period, ANA12 was injected at 0.5 mg/kg on day 27 and day 28 post injury. (D) (Left) Percentage of withdrawal threshold within 28 days post injury with and without ANA12 injection, (Right) bar graphs represent significant differences in percentage of withdrawal threshold among three groups on day 0, day 7, day 21, day 27 and day 28 post injury. Ordinary one-way ANOVA with Tukey’s multiple comparison test (*p<0.01, ***p<0.001, ns: non-significant, p>0.99). (E) Protein expression level of BDNF and TrkB in control, PCId7, PCId7+ANA12, PCId28 and PCId28+ANA12. (F) Normalization of BDNF expression in five groups. Unpaired-two-tailed-t-test, *p<0.05. (G) Immunohistochemistry representative images of GFAP and BNDF expression between ipsilateral and contralateral in control, PCId7+ANA12 and PCId28+ANA12. Scale bar: 10 µm.
© Exp Neurobiol
